Manfred Dietel

Active 1983–2023

158
Papers
28,683
Citations
99
h-index
157
i10-index

Citations

Citations per year for Manfred Dietel1977: 1 citations1984: 1 citations1986: 2 citations1987: 1 citations1988: 3 citations1989: 4 citations1990: 9 citations1991: 16 citations1992: 21 citations1993: 8 citations1994: 16 citations1995: 18 citations1996: 22 citations1997: 35 citations1998: 55 citations1999: 77 citations2000: 111 citations2001: 124 citations2002: 130 citations2003: 171 citations2004: 158 citations2005: 161 citations2006: 189 citations2007: 180 citations2008: 200 citations2009: 202 citations2010: 267 citations2011: 288 citations2012: 276 citations2013: 246 citations2014: 285 citations2015: 268 citations2016: 346 citations2017: 375 citations2018: 312 citations2019: 1,004 citations2020: 998 citations2021: 987 citations2022: 702 citations2023: 429 citations2024: 553 citations2025: 204 citations2026: 8 citations1978–1983: no citations, so these years are not shown1985: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,011 citing papers, 22.8% of this breakdownChina: 1,344 citing papers, 10.2% of this breakdownGermany: 1,044 citing papers, 7.9% of this breakdownUnited Kingdom: 749 citing papers, 5.7% of this breakdownItaly: 706 citing papers, 5.3% of this breakdownFrance: 563 citing papers, 4.3% of this breakdownJapan: 510 citing papers, 3.9% of this breakdownCanada: 465 citing papers, 3.5% of this breakdownAustralia: 364 citing papers, 2.7% of this breakdownNetherlands: 357 citing papers, 2.7% of this breakdownSpain: 343 citing papers, 2.6% of this breakdownSwitzerland: 299 citing papers, 2.3% of this breakdown
0%22.8%Other 26.1%

Fields

  • Medicine51.8%
  • Biochemistry, Genetics and Molecular Biology38.8%
  • Computer Science3.1%
  • Immunology and Microbiology2.9%
  • Agricultural and Biological Sciences0.6%
  • Chemistry0.5%
  • Other2.3%

Topics

  • Cancer Immunotherapy and Biomarkers6.2%
  • Cancer Genomics and Diagnostics3%
  • Lung Cancer Treatments and Mutations2.6%
  • Immunotherapy and Immune Responses2.3%
  • Cancer Cells and Metastasis2.2%
  • Lung Cancer Research Studies2%
  • Other81.7%

Coauthors

All papers

Open in search
  1. Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 1,783

  2. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Albrecht Stenzinger, Mark Stewart, Jeff Allen - Journal for ImmunoTherapy of Cancer 2020 cited by 506

  3. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Modern Pathology 2018 cited by 1,125

  4. Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 1,023

  5. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

    Authors: , , , , , , , , , , , - Annals of Oncology 2019 cited by 360

  6. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions

    Authors: , , , , , , - Genes Chromosomes and Cancer 2019 cited by 246

  7. Mucosal flora in inflammatory bowel disease

    Authors: , , , , , , , , , , - Gastroenterology 2002 cited by 1,333

  8. The landscape of metastatic progression patterns across major human cancers

    Authors: , , , , , , , , , , , , - Oncotarget 2014 cited by 302

  9. CD24 expression is a new prognostic marker in breast cancer.

    Authors: , , , , , , , , , , - 2003 cited by 307

  10. Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach

    Authors: , , , , , , , , - Scientific Reports 2012 cited by 241

  11. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

    Authors: , , , , , , , , , , , , , , , - Lung Cancer 2019 cited by 160

  12. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 401

  13. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

    Authors: , , , , , , , , , , - British Journal of Cancer 2008 cited by 479

  14. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

    Authors: , , , , , , , , , - BMC Cancer 2013 cited by 247

  15. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

    Authors: , , , , , , , , - The Lancet Oncology 2008 cited by 362

  16. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

    Authors: , , , , , , , , , , , - Thorax 2015 cited by 196

  17. Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

    Authors: , , , , , , , , , - Clinical Cancer Research 2008 cited by 371

  18. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism

    Authors: , , , , , , , , , , - Journal of Proteomics 2013 cited by 183

  19. Glutamate enrichment as new diagnostic opportunity in breast cancer

    Authors: , , , , , , , - International Journal of Cancer 2014 cited by 131

  20. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Schirmacher, Andreas Jung, Florian Haller, Wilko Weichert, Manfred Dietel - Journal of Thoracic Oncology 2020 cited by 112

  21. Guidance for laboratories performing molecular pathology for cancer patients

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Pathology 2014 cited by 211

  22. Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades

    Authors: , , , , , , , , - The Prostate 2004 cited by 189

  23. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.

    Authors: , , , , , - Arteriosclerosis An Official Journal of the American Heart Association Inc 1989 cited by 450

  24. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

    Authors: , , , , - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2016 cited by 253